SmartPA Criteria Proposal

Drug/Drug Class: Beta Adrenergic Agents, Nebulized PDL Edit
First Implementation Date: December 15, 2004
Revised Date: August 25, 2022
Prepared For: MO HealthNet
Prepared By: MO HealthNet/Conduent
Criteria Status: ☒ Revision of Existing Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Short-acting beta-agonists work quickly to relieve asthma symptoms. They relax the smooth muscles around the airways and are prescribed to use as needed to relieve shortness of breath most commonly associated with asthma. Overuse of these products is common and indicates that asthma is poorly controlled and that long-term control medications should be added or adjusted.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

<table>
<thead>
<tr>
<th>Preferred Agents</th>
<th>Non-Preferred Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albuterol Sulfate</td>
<td>Levalbuterol</td>
</tr>
<tr>
<td>Xopenex®</td>
<td></td>
</tr>
</tbody>
</table>

Type of Criteria: ☒ Preferred Drug List

Data Sources: ☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Beta Adrenergic Agents, Nebulized
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 1 preferred agent
  o Documented trial period of preferred agent
  o Documented ADE/ADR to preferred agent
### Denial Criteria

- Lack of adequate trial on required preferred agent
- Therapy will be denied if all approval criteria are not met
- **Cumulative quantity exceeds 120 vials per 60 days (excluding diagnosis of cystic fibrosis)**

### Required Documentation

<table>
<thead>
<tr>
<th>Laboratory Results:</th>
<th>Progress Notes:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MedWatch Form:</th>
<th>Other:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

### Default Approval Period

3 months

### References

- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.